In this downloadable slideset, expert faculty members Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, summarize key studies from this important annual conference.
Studies presented at the 2017 hepatology meeting in Washington, DC, sought to provide answers to questions surrounding mortality and HCC risk in patients with HCV who achieved SVR with DAA therapy. Here’s my take.
At AASLD 2017, exciting new data were presented on both current and investigational therapies for chronic HBV infection.
Here’s my take on how new data from AASLD 2017 on noninvasive imaging modalities and emerging investigational agents may affect the NAFLD/NASH patient management landscape.
How will data presented at AASLD 2017 on 8-week therapy have an impact on management of patients with HCV infection? Here’s my take.
Listen to downloadable audio from a series of live Webinars by Stephen A. Harrison, MD, COL (Ret.), FAASLD; Paul Y. Kwo, MD; and Norah Terrault, MD, MPH, FAASLD, in which the clinical impact of new data reported at the Washington, DC meeting is discussed.
*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.